Program: NSCLC therapeutic in combo. with checkpoint inhibitor + chemo
Stage: Phase 1/2a
Barinthus Biotherapeutics rights: Worldwide (76% of VOLT)(2)
Upcoming Milestones: Phase 1/2a interim data (Q1 2024)
(2) VOLT is 76% owned by Barinthus Biotherapeutics and 24% owned by the Ludwig Institute for Cancer Research
VTP-600: Immunotherapeutic candidate targeting MAGE-A3 and NY-ESO-1 Antigens
Strategic Collaboration with LUDWIG INSTITUTE FOR CANCER RESEARCH and CANCER RESEARCH UK
Lung cancer is the most frequent cause of cancer death worldwide. In 2020, approximately 2.2 million new cases were diagnosed and 1.8 million deaths occurred. Approximately 84% of lung cancers are cases classified as Non-Small Cell Lung Cancer (NSCLC). The most important histological distinction is squamous versus non-squamous, as it impacts selection of systemic therapy. About 25% to 30% of patients have tumors with squamous histology, which is associated with a worse prognosis and a worse response to chemotherapy. Better combination approaches are needed in first-line standard-of-care setting to improve long-term outcomes for NSCLC patients.
VTP-600 is a sequential combination immunotherapeutic candidate with ChAdOx and MVA components encoding tumor-associated antigens MAGE-A3 and NY-ESO-1.
MAGE-A3 and NY-ESO-1 are believed to be important target antigens for NSCLC as well as other tumors. MAGE-A3 and NY-ESO-1 are cancer/testis antigens, which are frequently expressed on cancer cells but have limited expression in normal tissues. MAGE-A3 is expressed in 48% of squamous NSCLC and 24% of non-squamous NSCLC. NY-ESO-1 has been shown to have an expression rate of 27% across all NSCLC types.
Barinthus Biotherapeutics has established a joint initiative with the Ludwig Institute for Cancer research and VOLT, to progress the clinical development of VTP-600. VTP-600 entered the clinic in December 2021 as part of a Phase 1/2a trial sponsored by Cancer Research UK. NSCLC patients are randomised to receive either VTP-600 in combination with standard of care (chemotherapy and anti-PD-1, pembrolizumab), or standard of care.
- Chen, X., et al. 2017. Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer. Oncology letters, 13(3), pp.1609-1618.
- Näslund, T.I., et al. 2007. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor. The Journal of Immunology, 178(11), pp.6761-6769.
- Coulie, P.G., Van den Eynde, B.J., Van Der Bruggen, P. and Boon, T., 2014. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nature Reviews Cancer, 14(2), p.135.
- Romero, P., et al. 2016. The Human Vaccines Project: A roadmap for cancer vaccine development. Science Translational Medicine, 8(334), pp.334ps9-334ps9.